BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3904908)

  • 1. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
    Bishop MC; Selby C; Taylor M
    Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate.
    Morales A; Nickel JC
    Urology; 1985 Nov; 26(5):477-81. PubMed ID: 3904134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate.
    Fosså SD; Fosså J; Aakvaag A
    J Urol; 1977 Dec; 118(6):1013-8. PubMed ID: 926240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol.
    Daponte D; Sylvester R; De Pauw M; Fryszman A; Smith RM; Smith PH
    Br J Urol; 1983 Aug; 55(4):408-12. PubMed ID: 6349745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
    Hauchecorne J
    Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
    [No Abstract]   [Full Text] [Related]  

  • 8. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin.
    Daehlin L; Damber JE; von Schoultz B; Bergman B
    Br J Urol; 1986 Aug; 58(4):412-6. PubMed ID: 3092893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy.
    Harper ME; Peeling WB; Cowley T; Brownsey BG; Phillips ME; Groom G; Fahmy DR; Griffiths K
    Acta Endocrinol (Copenh); 1976 Feb; 81(2):409-26. PubMed ID: 946155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC; Gill GM; Cummings KB
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
    Daponte DP; Stevens I; Robinson MR
    Actas Urol Esp; 1986; 10(6):437-40. PubMed ID: 3825644
    [No Abstract]   [Full Text] [Related]  

  • 13. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
    Benson RC; Cummings K
    Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens.
    Boyns AR; Cole EN; Phillips ME; Hillier SG; Cameron EH; Griffiths K; Shahmanesh M; Feneley RC; Hartog M
    Eur J Cancer (1965); 1974 Jul; 10(7):445-9. PubMed ID: 4376085
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of estramustine phosphate on plasma testosterone during treatment of carcinoma of prostate.
    Kjaer TB; Nilsson T; Madsen PO
    Urology; 1975 Jun; 5(6):802-4. PubMed ID: 1136096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study of cyproterone acetate and estramustine phosphate on the plasma levels of testosterone and gonadotrophic hormones in adenocarcinoma of the prostate].
    Alfonso Sánchez M; Pérez Herrero F; Urrutia Avisrror M; Vega Wong J; Lago Montero A
    Actas Urol Esp; 1986; 10(2):111-6. PubMed ID: 2942009
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostatic cancer. Transcortin levels during treatment with estramustine phosphate.
    Sandberg AA; Rosenthal H; Mittelman A; Murphy GP
    Urology; 1975 Jul; 6(1):17-21. PubMed ID: 1145919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal effects of different doses of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
    Fritjofsson A; Norlén BJ; Högberg B; Rajalakshmi M; Cekan SZ; Diczfalusy E
    Scand J Urol Nephrol; 1981; 15(1):37-44. PubMed ID: 6787701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EORTC Phase III trials in prostatic cancer.
    Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
    Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
    [No Abstract]   [Full Text] [Related]  

  • 20. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
    Smith PH; Robinson M; Richards B; Suciu S; De Pauw M; Sylvester R; Denis L
    Urology; 1984 Jun; 23(6 Suppl):64-8. PubMed ID: 6375083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.